Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Inflammation 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2330Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Ashwagandha × Clear all
NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

University of Louisville

Phase 1/2 Recruiting
72 enrolled
Gynecologic

Ovarian Neoplasms

NCT04092647 2023-06-15

Ashwagandha for Cognitive Dysfunction

Sutter Health

Phase 2 Unknown
80 enrolled

Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction

NCT00689195 2011-06-23

OSCAT

Tata Memorial Hospital

Phase 1/2 Unknown
24 enrolled
Sarcoma

Osteosarcoma

NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

National University of Natural Medicine

Phase 1 Completed
25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡